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Fludarabine-induced bra-
dycardia in a patient with 
refractory leukemia 
To the Editor: A 22ryearrold 
male diagnosed with acute myelogr
enous leukemia in November 2005 
achieved complete remission after 
two courses of induction chemor
therapy with idarubicin (12 mg/
m2 intravenously for 3 days) and 
cytosine arabinoside (200 mg/m2 
in a 24rhour infusion for 7 days). 
He then received an additional two 
courses of cytosine arabinoside 
(3000 mg/m2) in a 3rhour continur
ous intravenous infusion twice daily 
for 3 days in April 2006 for intenr
sification. Six months later, the leur
kemia relapsed and was refractory 
to rerinduction chemotherapy (idar
rubicin 12 mg/m2 on days 1r3 and 
cytosine arabinoside 200 mg/m2 on 
days 1r7). With the exception of 
myelosuppression, no toxic events 
occurred during idarubicin and cyr
tosine arabinoside treatment. Due 
to the refractoriness to rerinducr
tion chemotherapy, salvage chemor
therapy with the FLAGI regimen 
(fludarabine 30 mg/m2 on days 1r5, 
cytosine arabinoside 2000 mg/m2 
on days 1r5, and idarubicin 12 mg/
m2 on days 7r8) was prescribed. 
Before chemotherapy, his vital signs 
were stable, with a blood pressure of 
111/65 mm Hg, a respiratory rate of 
19/min, a heart rate of 97/min, and 
a body temperature of 36.6ºC. An 
electrocardiogram (ECG) showed 
a normal sinus rhythm (Figure 
1a). Premedication included dexar
methasone, granisetron, and metor
clopramide, which were prescribed 
in previous chemotherapy. Thirty 
minutes after the fludarabine infur
sion had been started, he developed 
suddenronset general weakness, 
which lessened 5 minutes later. At 
that time, persistent bradycardia 
(48 beats per minute) was noted; 
vital signs were otherwise norr
mal (blood pressure, 120/70 mm 
Hg; respiratory rate, 20/min; and 
body temperature, 36.1ºC). ECG 
revealed sinus bradycardia but no 
atrioventricular block, ST segment 
elevation or depression, or T wave 
inversion (Figure 1b). The patient 
did not have chest tightness or 
pain, dizziness, cold sweats, palpitar
tions, dyspnea, or fever with chills. 
Investigations showed serum potasr
sium 4.9 mmol/L (normal, 3.5r4.5 
mmol/L), creatinine 1.0 gm/dL 
(normal, 0.5r1.3 g/dL), CPK 19 
IU/L (normal, 38r174 IU/L), crer
atine kinase MB fraction 2.7 U/L 
(normal, 3r10 U/L), and troponin 
I < 0.04 ng/ml (normal, <0.8 ng/
mL). No specific therapy was adr
ministered; however, oxygen was 
given at 4 L/min via nasal cannula. 
The persistent bradycardia resolved 
gradually, 3 hours after cessation 
of the 5rday fludarabine infusion 
(Figure 1c); he then received 2 days 
of idarubicin treatment without inr
cident (Figure 2). 
Cytosine arabinoside is frer
quently used in the treatment of 
hematologic malignancies, esper
cially acute myelogenous leukemia. 
Sporadic cases of pericarditis, perir
Figure 1a. eCg findings before the start of therapy. 
Figure 1b. eCg on day 1-5 of fludarabine infusion. 
Figure 1c. eCg on the day following infusion of fludarabine. 
Figure 2. Correlation between heart rate and Flagi regimen infusion. 
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cardial effusion, cardiac tamponr
ade, congestive heart failure, and 
sinus bradycardia have previously 
been reported as complications of 
cytosine arabinoside.1r3 Fludarabine 
is a purine antagonist that is comr
monly used for patients with nonr
Hodgkin lymphoma and chronic 
lymphocytic leukemia. The most 
common adverse effects are myelor
suppression and immunosuppresr
sion. Cardiovascular complications 
of fludarabine are rare, although 
several cases of congestive heart 
failure or left ventricular failure 
have been reported.4r5 
There are many possible etir
ologies for the bradycardia seen in 
the present patient. For example, 
sepsis, cardiogenic events, electror
lyte imbalance, and drugs such as 
cytosine arabinoside may all cause 
bradycardia. An adverse drug reacr
tion is considered to be the probr
able cause of the bradycardia in this 
patient because no other etiologies 
were apparent. Cytosine arabinor
side seemed an unlikely cause of 
bradycardia because the patient 
had received cytosine arabinosider
containing chemotherapy previousr
ly. The bradycardia occurred during 
fludarabine treatment and subsided 
significantly after completion of the 
infusion of this drug. Other probr
able causes of bradycardia had alr
ready been excluded and therefore 
it is reasonable to speculate about 
a possible relationship between 
fludarabine and the sinus bradyr
cardia observed in this patient. 
Clinicians should be aware of this 
potential toxic effect of fludarabine, 
especially in view of its increased 
use in the treatment of hematologic 
diseases. 
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Bronchiolitis obliterans 
following hematopoietic 
stem cell transplantation 
To the Editor: One of the most 
important causes of morbidity 
and mortality after hematopoietic 
stem cell transplantation (HSCT) 
is bronchiolitis obliterans (BO), 
which sometimes leads to irreversr
ible and progressive air flow obr
struction (AFO).1r3 Usually this 
complication is seen after alloger
neic transplantation in up to 26% of 
cases.4 The usual diagnostic method 
is spirometry. Other modalities are 
high resolution computed tomograr
phy (HRCT) and lung biopsy. The 
most well known and consistent 
risk factor for BO is chronic graftr
versusrhost disease (GVHD).4,5
This crossrsectional study was 
carried out at the Shariati Hospital, 
Hematology, Oncology and Stem 
Cell Transplantation Research 
Center to compare diagnostic 
methods and to determine addir
tional risk factors by two diagnostic 
methods. The patients who had alr
logeneic HSCTs at least six months 
previously were included in the 
study and followed from January to 
June 2009. Exclusion criteria were 
current smoking or a history of 
smoking, history of asthma, chronic 
obstructive pulmonary disease or 
bronchiectasis, transplantation 
more than one time and abnormal 
spirometry with an FEV1/FVC less 
than 70%. All of the patients underr
went spirometry and chest HRCT 
in the inspiratory and expiratory 
phase. Spirometric criteria for dir
agnosis of bronchiolitis obliterans 
without consideration of the age of 
the patient is defined as FEV1/FVC 
less than 75% or a more than 10% 
decrement of FEV1/FVC from the 
baseline value. HRCT criteria were 
air trapping or a mosaic pattern, 
which is exaggerated on expiratory 
views. A diagnosis of bronchiolitis 
obliterans requires one of the spiror
metric or imaging criteria.
Fortyrtwo patients completed 
the study. Nineteen (45.2%) met 
the diagnostic criteria for BO, but 
only 11 (26.2%) had abnormal spir
rometry and 17 (40.5%) patients 
had air trapping and a mosaic patr
tern in the chest HRCT that was 
compatible with a diagnosis of BO. 
Eleven (26.2%) patients had a hisr
tory of acute GVHD and 21 (50%) 
had a history of chronic GVHD. 
Only 10 (23.8%) had no history 
of acute or chronic GVHD. There 
was a statistically meaningful corr
relation between BO and GVHD 
(P=.037); only one case of BO was 
in the nonrGVHD group (10%), 
6 cases in the acute GVHD group 
(54.5%) and 12 cases were in the 
chronic GVHD group (57.1%). 
Ten patients (23.8%) were less than 
20 years old, 22 were in the 21r40 
yearrold group (52.4%) and 10 par
tients (23.8%) were older than 41 
years.
This article is reprint a that was 
originally published in the Annals 
of Saudi Medicine 2010;30(3):246r
247.
